Gut microbiota modulation target

The “gut microbiota modulation target” does not refer to a single molecule or receptor but rather to strategies aimed at altering the composition or activity of the complex community of microorganisms residing in the human gastrointestinal tract. The gut microbiome includes bacteria, fungi, protozoa, and viruses whose collective metabolic activities influence host health through nutrient absorption, immune regulation, production of bioactive compounds like vitamins and neurotransmitter precursors—and via crosstalk along axes such as gut-brain or gut-lung. Therapeutic approaches targeting this system include administration of probiotics/prebiotics/synbiotics/postbiotics or fecal transplantation to restore balance (“eubiosis”) when disrupted (“dysbiosis”). Such interventions are being explored for prevention/treatment across a spectrum including inflammatory diseases, metabolic disorders like diabetes/cardiovascular disease, infections—including those outside the GI tract—and stress-related psychological conditions. However—as this is not a discrete molecular entity—the term “gut microbiota modulation target” is imprecise for structured drug-target databases focused on individual proteins/receptors/enzymes/transporters.

Other names

Gut microbiome modulationMicrobiota modulationModulation of gut microbiotaMicrobiome-targeted therapy

Modulation is achieved through altering microbial composition and function using probiotics (live beneficial microbes), prebiotics (substrates for beneficial microbes), synbiotics (combination), postbiotics (inactivated microbes or their components), dietary changes, and fecal microbiota transplantation. These interventions can enhance production of beneficial metabolites such as short-chain fatty acids and antimicrobial peptides; maintain mucosal integrity; stimulate immune responses; and reduce dysbiosis-associated inflammation.